Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DGX Stock Forecast 2026-2027
$195.02
Current Price
$21.59B
Market Cap
Buy 9
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to DGX Price Targets
+20.5%
To High Target of $235.00
+12.6%
To Median Target of $219.50
-5.7%
To Low Target of $184.00
DGX Price Momentum
+1.1%
1 Week Change
-0.1%
1 Month Change
+19.1%
1 Year Change
+12.4%
Year-to-Date Change
-8.7%
From 52W High of $213.50
+21.9%
From 52W Low of $160.02
📊 TOP ANALYST CALLS
Did DGX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Quest Diagnostics is one of their latest high-conviction picks.
Latest DGX Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, DGX has a bullish consensus with a median price target of $219.50 (ranging from $184.00 to $235.00). The overall analyst rating is Buy (7.9/10). Currently trading at $195.02, the median forecast implies a 12.6% upside. This outlook is supported by 9 Buy, 8 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ann Hynes at Mizuho, projecting a 20.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DGX Analyst Ratings
9
Buy
8
Hold
0
Sell
DGX Price Target Range
Low
$184.00
Average
$219.50
High
$235.00
Current: $195.02
Latest DGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2026 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $210.00 |
| Feb 12, 2026 | Mizuho | Ann Hynes | Outperform | Maintains | $235.00 |
| Feb 11, 2026 | Barclays | Stephanie Davis | Overweight | Maintains | $225.00 |
| Feb 11, 2026 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $220.00 |
| Feb 11, 2026 | UBS | Kevin Caliendo | Neutral | Maintains | $210.00 |
| Feb 11, 2026 | Jefferies | Tycho Peterson | Buy | Maintains | $220.00 |
| Feb 11, 2026 | Truist Securities | David Macdonald | Hold | Maintains | $220.00 |
| Feb 10, 2026 | Citigroup | Patrick Donnelly | Neutral | Maintains | $215.00 |
| Oct 27, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $200.00 |
| Oct 22, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $205.00 |
| Oct 22, 2025 | Barclays | Stephanie Davis | Equal-Weight | Maintains | $195.00 |
| Oct 21, 2025 | Leerink Partners | Michael Cherny | Outperform | Maintains | $210.00 |
| Oct 21, 2025 | Jefferies | Tycho Peterson | Buy | Maintains | $215.00 |
| Oct 17, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $210.00 |
| Oct 17, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $190.00 |
| Oct 8, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $190.00 |
| Oct 2, 2025 | Barclays | Stephanie Davis | Equal-Weight | Maintains | $190.00 |
| Aug 25, 2025 | Baird | Eric Coldwell | Neutral | Downgrade | $194.00 |
| Jul 23, 2025 | Deutsche Bank | Pito Chickering | Hold | Maintains | $178.00 |
| Jul 23, 2025 | UBS | Kevin Caliendo | Neutral | Maintains | $180.00 |
Quest Diagnostics Inc. (DGX) Competitors
The following stocks are similar to Quest Diagnostics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Quest Diagnostics Inc. (DGX) Financial Data
Quest Diagnostics Inc. has a market capitalization of $21.59B with a P/E ratio of 22.3x. The company generates $11.03B in trailing twelve-month revenue with a 9.0% profit margin.
Revenue growth is +7.1% quarter-over-quarter, while maintaining an operating margin of +14.0% and return on equity of +14.8%.
Valuation Metrics
Market Cap
$21.59B
Enterprise Value
$27.71B
P/E Ratio
22.3x
PEG Ratio
1.9x
Price/Sales
2.0x
Growth & Margins
Revenue Growth (YoY)
+7.1%
Gross Margin
+32.4%
Operating Margin
+14.0%
Net Margin
+9.0%
EPS Growth
+10.4%
Financial Health
Cash/Price Ratio
+2.0%
Current Ratio
1.0x
Debt/Equity
90.4x
ROE
+14.8%
ROA
+6.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Quest Diagnostics Inc. (DGX) Business Model
About Quest Diagnostics Inc.
What They Do
Provides diagnostic testing and information services.
Business Model
The company primarily generates revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing conducted via a network of around 2,300 patient service centers, doctors' offices, and hospitals. Additionally, it offers diagnostic solutions including clinical trials testing, risk-assessment services, and IT solutions for healthcare providers.
Additional Information
Quest Diagnostics serves a significant portion of the U.S. population, impacting one in three adults and half of U.S. physicians and hospitals annually. They engage in joint ventures for regional laboratory services and have introduced advanced testing innovations, reinforcing their position in the healthcare diagnostics sector.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
45,000
CEO
Mr. James E. Davis
Country
United States
IPO Year
1996
Website
www.questdiagnostics.comQuest Diagnostics Inc. (DGX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Analysts Estimate Chemed (CHE) to Report a Decline in Earnings: What to Look Out for
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 16, 2026
By Zacks Equity Research
Tale of the Tape
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 14, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Quest Diagnostics partners with City of Hope to implement the Haystack MRD ctDNA Test in 14 U.S. sites, aiding clinical trials for patients with solid tumors like breast and colorectal cancer.
Why It Matters
The collaboration between Quest Diagnostics and City of Hope enhances cancer treatment precision, potentially increasing demand for diagnostic services and impacting Quest's market position and revenue growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Quest Diagnostics (DGX) is not expected to meet key criteria for a likely earnings beat in its upcoming earnings report. Investors should be cautious.
Why It Matters
Quest Diagnostics may underperform in its earnings report, indicating potential stock price decline and impacting investor sentiment and strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
DGX is expected to show steady growth in Q1 earnings; however, estimate cuts and a negative earnings surprise prediction (ESP) may impact the overall outlook.
Why It Matters
Estimate cuts and a negative Earnings Surprise Prediction (ESP) for DGX may indicate weaker-than-expected performance, potentially affecting stock price and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores can help identify high-potential stocks, guiding investors toward those likely to outperform the market and enhance portfolio returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Quest Diagnostics (NYSE: DGX) will report its Q1 2026 financial results on April 21, 2026, before market opening.
Why It Matters
Quest Diagnostics' upcoming Q1 2026 financial results could impact stock performance, influencing investor sentiment and market expectations based on earnings trends and guidance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The aging population and increased AI adoption are driving demand in the outpatient and home healthcare sector, benefiting companies like DGX, DVA, OPCH, and ADUS.
Why It Matters
Aging demographics and AI integration drive growth in outpatient and home healthcare, positively impacting companies like DGX, DVA, OPCH, and ADUS, suggesting potential investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About DGX Stock
What is Quest Diagnostics Inc.'s (DGX) stock forecast for 2026?
Based on our analysis of 31 Wall Street analysts, Quest Diagnostics Inc. (DGX) has a median price target of $219.50. The highest price target is $235.00 and the lowest is $184.00.
Is DGX stock a good investment in 2026?
According to current analyst ratings, DGX has 9 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $195.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DGX stock?
Wall Street analysts predict DGX stock could reach $219.50 in the next 12 months. This represents a 12.6% increase from the current price of $195.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Quest Diagnostics Inc.'s business model?
The company primarily generates revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing conducted via a network of around 2,300 patient service centers, doctors' offices, and hospitals. Additionally, it offers diagnostic solutions including clinical trials testing, risk-assessment services, and IT solutions for healthcare providers.
What is the highest forecasted price for DGX Quest Diagnostics Inc.?
The highest price target for DGX is $235.00 from Ann Hynes at Mizuho, which represents a 20.5% increase from the current price of $195.02.
What is the lowest forecasted price for DGX Quest Diagnostics Inc.?
The lowest price target for DGX is $184.00 from at , which represents a -5.7% decrease from the current price of $195.02.
What is the overall DGX consensus from analysts for Quest Diagnostics Inc.?
The overall analyst consensus for DGX is bullish. Out of 31 Wall Street analysts, 9 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $219.50.
How accurate are DGX stock price projections?
Stock price projections, including those for Quest Diagnostics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:38 AM UTC